Personalized Medicine Beyond Stratification
Publisher
Springer Netherlands
Reference62 articles.
1. Aartsma-Rus A, van Roon-Mom W, Lauffer M, Siezen C, Duijndam B, Coenen-de Roo T, Schule R, Synofzik M, Graessner H (2023) Development of tailored splice-switching oligonucleotides for progressive brain disorders in Europe: development, regulation, and implementation considerations. RNA 29(4):446–454. https://doi.org/10.1261/rna.079540.122
2. Andreoletti M (2018) More than one way to measure? A casuistic approach to cancer clinical trials. Perspect Biol Med 61(2):174–190. https://doi.org/10.1353/pbm.2018.0035
3. Balouiri M, Sadiki M, Ibnsouda SK (2016) Methods for in vitro evaluating antimicrobial activity: a review. J Pharm Anal 6(2):71–79. https://doi.org/10.1016/j.jpha.2015.11.005
4. Beckmann JS, Lew D (2016) Reconciling evidence-based medicine and precision medicine in the era of big data: challenges and opportunities. Genome Med 8(1):134. https://doi.org/10.1186/s13073-016-0388-7
5. Boenink M (2009) Tensions and opportunities in convergence: shifting concepts of disease in emerging molecular medicine. NanoEthics 3(3):243–255. https://doi.org/10.1007/s11569-009-0078-7